Investigating cellular responses to novel chemotherapeutics in renal cell carcinoma using SR-FTIR spectroscopy.
Investigating cellular responses to novel chemotherapeutics in renal cell carcinoma using SR-FTIR spectroscopy.
复制标题
使用 SR-FTIR 光谱研究肾细胞癌细胞对新型化疗药物的反应。
DOI：
10.1039/c2an35632e
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
P. Gardner
中科院分区：
文献类型：
--
作者：
C. Hughes;M. Brown;N. Clarke;K. R. Flower;P. Gardner
SR-FTIR光谱学被评价为当癌细胞暴露于化疗药物时，在单细胞水平区分细胞反应的光谱信号的技术。5-氟尿嘧啶，一种已知作用模式的确定药物，与两种基于金的化合物的实验类似物沿着针对肾癌细胞系（Caki-2）进行了测试。使用无监督的主成分分析（PCA）未能清楚地定义对照和药物处理的细胞光谱之间的任何区别。有监督的主成分线性判别分析（PC-LDA）确实有一定的潜力，揭示细胞反应和修复的签名，但再次未能明确区分不同药物治疗的光谱组。或者，通过单点台式光谱法在来自平均细胞群体的光谱中观察到清晰的PCA区分，同时用增加的孔径探测几个细胞。Caki-2细胞系最初似乎对新化合物敏感，在通过PCA和细胞活力测定评估的基本细胞恢复之前诱导细胞应答。
SR-FTIR spectroscopy was evaluated as a technique to discriminate spectral signals of cellular response at the single cell level, when cancer cells are exposed to chemotherapeutics. 5-Fluorouracil, an established drug of known mode of action, was tested against a renal carcinoma cell line (Caki-2), along with two experimental analogues of gold-based compounds. The use of unsupervised principal component analysis (PCA) failed to clearly define any distinction between control and drug treated cell spectra. Supervised principal component linear discriminant analysis (PC-LDA) did have some potential to reveal signatures of cell response and repair but again failed to distinctly discriminate groups of spectra with different drug treatments. Alternatively, clear PCA discrimination was observed in spectra from average cell populations via single point benchtop spectroscopy, probing several cells simultaneously with an increased aperture. The Caki-2 cell line initially appeared to be sensitive to the novel compounds, inducing a cellular response prior to subsequential cell recovery which was assessed by both PCA and cell viability assays.